News & Articles ribose TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients With Ovarian Cancer WALTHAM, Mass. -- TESARO, Inc. , an oncology-focused biopharmaceutical company, today announced that it has initiated patient enrollment in a Phase 3 trial of niraparib, an inhibitor of poly ADP-ribose ... July 23, 2013 - GlobeNewswire via Yahoo! Finance